Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Background: The estimated annual prevalence of drug use disorders is as high as 3%, underpinning the need to continually develop more effective treatments. Central nervous system dysregulation, contributing to acute and post-withdrawal syndromes, has traditionally been managed with
benzodiazepines; however, a small but growing body of data indicate that the GABAA receptor antagonist, flumazenil, may offer some advantages over traditional management.
Aim: To review the literature on the safety and efficacy of flumazenil in benzodiazepine use disorders and identify gaps in the literature.
Method: A systematic method was used to identify randomised control trials. Where randomised control trials existed, non-randomised control trials were included to supplement findings.
Results: Eleven flumazenil trials were included with varying doses, frequencies and routes of administration. The evidence for flumazenil alone showed generally a reduction in withdrawal symptoms with the exception of one study where withdrawal symptoms initially increased. Flumazenil plus
benzodiazepine tapering was assessed in one randomised control trial and a series of non-randomised control trials. Randomised control trial results showed that flumazenil plus benzodiazepine tapering was superior at reducing withdrawal symptoms compared to benzodiazepine tapering alone and
placebo. Flumazenil was associated with no serious adverse events; however there remains a risk of seizures.
Conclusion: Although flumazenil shows promising efficacy in the management of benzodiazepine use disorders and withdrawal, more randomized control trials are required before a definitive recommendation can be made around its use.
Original languageEnglish
Pages (from-to)211-220
JournalJournal of Psychopharmacology
Volume35
Issue number3
DOIs
Publication statusPublished - Mar 2021

Fingerprint

Dive into the research topics of 'Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data'. Together they form a unique fingerprint.

Cite this